1.56

7.59% 0.11

After Hours: 1.56

Coherus Oncology Inc (CHRS)

Overview News Price History Option Chain Financials Why CHRS Down? Discussions Forecast

Coherus Oncology Inc stock is traded at $1.56, with a volume of 1.53M. It is up +7.59% in the last 24 hours and up +7.59% over the past month. Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Previous Close:

$1.45

Open:

$1.44

24h Volume:

1.53M

Relative Volume:

1.40

Market Cap:

$240.63M

Revenue:

$42.17M

Net Income/Loss:

$-183.12M

P/E Ratio:

-1.0713

EPS:

-1.4562

Net Cash Flow:

$-138.51M

1W Performance:

+7.59%

1M Performance:

+7.59%

6M Performance:

+14.71%

1Y Performance:

+92.59%

1-Day Range:

$1.425

$1.60

1-Week Range:

$1.39

$1.60

52-Week Range:

$0.733

$2.6158

Coherus Oncology Inc Stock (CHRS) Company Profile

Name

Coherus Oncology Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

(650) 649-3530

Address

C/O DENNIS M. LANFEAR, REDWOOD CITY, CA

Employee

145

Twitter

@coherus_bio

Next Earnings Date

2026-08-06

Latest SEC Filings

CHRS's Discussions on Twitter

Compare CHRS vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CHRS Coherus Oncology Inc	1.56	215.95M	42.17M	-183.12M	-138.51M	-1.4562
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-23-26	Initiated	Oppenheimer	Outperform
Sep-04-25	Upgrade	Maxim Group	Hold → Buy
Aug-16-24	Downgrade	UBS	Buy → Neutral
Nov-17-23	Initiated	Robert W. Baird	Outperform
Nov-08-23	Downgrade	Maxim Group	Buy → Hold
Jul-24-23	Initiated	Citigroup	Buy
May-01-23	Initiated	Truist	Buy
Mar-28-23	Upgrade	UBS	Neutral → Buy
Jun-14-22	Initiated	UBS	Neutral
Mar-07-22	Downgrade	JP Morgan	Overweight → Neutral
Jul-16-20	Initiated	BofA Securities	Neutral
Apr-17-20	Initiated	SunTrust	Buy
Aug-13-19	Initiated	Mizuho	Buy
Aug-02-19	Reiterated	H.C. Wainwright	Buy
Aug-02-19	Reiterated	Maxim Group	Buy
Jun-11-19	Initiated	Barclays	Overweight
May-07-19	Initiated	H.C. Wainwright	Buy
Aug-28-18	Initiated	H.C. Wainwright	Buy
Mar-09-18	Reiterated	Maxim Group	Buy
Aug-08-17	Reiterated	JP Morgan	Overweight
Jun-13-17	Reiterated	Maxim Group	Buy
May-05-17	Initiated	BMO Capital Markets	Outperform
Oct-19-16	Initiated	Robert W. Baird	Outperform
Sep-07-16	Initiated	Maxim Group	Buy
Jul-27-16	Initiated	Citigroup	Buy
Jan-20-16	Initiated	Credit Suisse	Outperform

View All

Coherus Oncology Inc Stock (CHRS) Latest News

Jul 01, 2026

Coherus Oncology, Inc. Financial Disclosures & Filings - TradingView

Jul 01, 2026

Jun 30, 2026

Free cash flow per share of Coherus Oncology, Inc. – SWB:8C5 - TradingView

Jun 30, 2026

Jun 26, 2026

Enterprise value to EBITDA forward of Coherus Oncology, Inc. – NASDAQ:CHRS - TradingView

Jun 26, 2026

CHRS Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Enterprise value to EBITDA forward of Coherus Oncology, Inc. – LS:A12ETZ - TradingView

Jun 26, 2026

Coherus Oncology (CHRS) Jefferies Global Healthcare Conference 2026 Summary - Quartr

Jun 24, 2026

Coherus Oncology (CHRS) Proxy filing Summary - Quartr

Jun 24, 2026

Coherus Oncology (CHRS) Enters Clinical Collaboration for Phase 1 Trial - GuruFocus

Jun 24, 2026

Jun 23, 2026

Coherus Enters Trial Collaboration, Supply Agreement With Zumutor Biologics - marketscreener.com

Jun 23, 2026

Coherus and Zumutor announce phase 1 cancer trial collaboration - Investing.com

Jun 23, 2026

Coherus and Zumutor announce phase 1 cancer trial collaboration By Investing.com - Investing.com India

Jun 23, 2026

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi) - The Manila Times

Jun 23, 2026

Coherus Oncology and Zumutor Biologics Announce Phase 1 Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI - Quiver Quantitative

Jun 23, 2026

Coherus and Zumutor Biologics Announce Clinical - GlobeNewswire

Jun 23, 2026

Coherus doses first patient in cancer combo trial with Zumutor - Stock Titan

Jun 23, 2026

Coherus Oncology (CHRS) Slides Amid Sector Weakness, Testing Key Support LevelsBox Spread - dars.gov.et

Jun 23, 2026

Jun 18, 2026